These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19318330)

  • 21. Ten remarkable years.
    Sledge GW
    Clin Breast Cancer; 2010 Jun; 10(3):178. PubMed ID: 20497915
    [No Abstract]   [Full Text] [Related]  

  • 22. Glandular Paget's disease of the nipple.
    Shousha S
    Histopathology; 2007 May; 50(6):812-4. PubMed ID: 17376174
    [No Abstract]   [Full Text] [Related]  

  • 23. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Target-based therapies in breast cancer: current status and future perspectives.
    Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
    Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER-2/neu analysis in breast cancer bone metastases.
    Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
    J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating in the dark: unanswered questions on costs and benefits of late line therapy for metastatic breast cancer.
    Anders CK; Peppercorn J
    Cancer Invest; 2009 Jan; 27(1):13-6. PubMed ID: 19160108
    [No Abstract]   [Full Text] [Related]  

  • 27. [Minutes from the May 19th, 2006 meeting of the Oncology and Radiotherapy College. Location: National Institute of Oncology, Conference Hall. Present are 16 College members and invited guests].
    Moskovits K; Szucs M
    Magy Onkol; 2006; 50(3):265, 268-9, 271. PubMed ID: 17201055
    [No Abstract]   [Full Text] [Related]  

  • 28. Lapatinib (Tykerb) for advanced breast cancer.
    Med Lett Drugs Ther; 2007 Sep; 49(1269):74-5. PubMed ID: 17848906
    [No Abstract]   [Full Text] [Related]  

  • 29. Adjuvant anthracyclines and taxanes: quantifying the costs of therapeutic advances in breast cancer.
    Morris PG; Bach PB
    Onkologie; 2009 Sep; 32(8-9):464-6. PubMed ID: 19745589
    [No Abstract]   [Full Text] [Related]  

  • 30. The breast cancer market.
    Syed BA
    Nat Rev Drug Discov; 2015 Apr; 14(4):233-4. PubMed ID: 25829273
    [No Abstract]   [Full Text] [Related]  

  • 31. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
    Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
    Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lapatinib for inflammatory breast cancer.
    Hall PS; Hanby A; Cameron DA
    Lancet Oncol; 2009 Jun; 10(6):538-9. PubMed ID: 19482243
    [No Abstract]   [Full Text] [Related]  

  • 33. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?
    Petrelli F; Cabiddu M; Ghilardi M; Barni S
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1467-77. PubMed ID: 19737114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Her-2/neu evaluation in Sister Mary Joseph's nodule from breast carcinoma: a case report and review of the literature.
    Brunelli M; Manfrin E; Miller K; Eccher A; Gobbo S; Reghellin D; Chilosi M; Remo A; Martignoni G; Menestrina F; Bonetti F
    J Cutan Pathol; 2009 Jun; 36(6):702-5. PubMed ID: 19515052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapy of triple-negative breast cancer.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tufted hair folliculitis in a woman treated with lapatinib for breast cancer.
    Ena P; Fadda GM; Ena L; Farris A; Santeufemia DA
    Clin Exp Dermatol; 2008 Nov; 33(6):790-1. PubMed ID: 18627387
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.
    Miglietta L; Vanella P; Canobbio L; Parodi MA; Guglielmini P; Boccardo F
    Anticancer Res; 2009 May; 29(5):1621-5. PubMed ID: 19443376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Sustainability and new anticancer drugs].
    Perrone F
    Recenti Prog Med; 2015 Jan; 106(1):11-3. PubMed ID: 25621773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The breast cancer drug market.
    Wilcock P; Webster RM
    Nat Rev Drug Discov; 2021 May; 20(5):339-340. PubMed ID: 33483705
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost effectiveness, chemotherapy, and the clinician.
    Griggs JJ; Sorbero ME
    Breast Cancer Res Treat; 2009 Apr; 114(3):597-8. PubMed ID: 18695985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.